ORA - Oxford University Research Archive

« Previous | 1 - 10 of 22 | Next »

1

Journal article

Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells

Xue, L, Salimi, M, Panse, I, et al.
2013-12-05

2

Journal article

Prostaglandin D2 and leukotriene E4 synergize to stimulate diverse TH2 functions and TH2 cell/neutrophil crosstalk.

Xue, L, Fergusson, J, Salimi, M, et al.
2015-05-05

3

Journal article

A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis.

Salimi, M, Barlow, JL, Saunders, SP, et al.
2013-12-05

4

Conference item

Interaction of type 2 cytotoxic T lymphocytes and mast cell lipid mediators contributes to pathogenesis of eosinophilic asthma

Conference abstract
Xue, L, Stoeger, L, Marchi, E, et al.
2017-05-23

5

Journal article

PGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2.

Schröder, R, Xue, L, Konya, V, et al.
2012

6

Journal article

Genome-wide physical activity interactions in adiposity - A meta-analysis of 200,452 adults.

Graff, M, Scott, RA, Justice, AE, et al.
2017-04-04

7

Journal article

Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma

Hilvering, B, Hinks, TSC, Stoeger, L, et al.
2018-06-15

8

Journal article

Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a

Cheung, KL, Jarrett, RGA, Subramaniam, S, et al.
2016-10-26

9

Conference item

Fevipiprant, a selective prostaglandin D(2)receptor 2 antagonist, potently inhibits chemotaxis and cytokine production by Tc2 cells (type-2 CD8(+)lymphocytes)

Xue, L, Chen, W, Luo, J, et al.
2019-05-22

10

Journal article

Diagnosing eosinophilic asthma using a multivariate prediction model based on blood granulocyte responsiveness.

Hilvering, B, Vijverberg, SJ, Jansen, J, et al.
2016-12-28

TO TOP